anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND: Ibuprofen is one of the most commonly used analgesic and antipyretic drugs in children. However, its potential causal role in childhood asthma pathogenesis remains uncertain. In this systematic review, we assessed the association between ibuprofen administration in children and the risk of developing or exacerbating asthma.
METHODS: We searched MEDLINE, Embase, Cochrane Library, CINAHL, Web of Science, and Scopus from inception to May 2022, with no language limits; searched relevant reviews; and performed citation searching. We included studies of any design that were primary empirical peer-reviewed publications, where ibuprofen use in children 0-18 years was reported. Screening was performed in duplicate by blinded review. In total, 24 studies met our criteria. Data were extracted according to PRISMA guidelines, and the risk of bias was assessed using RoB2 and NOS tools. Quantitative data were pooled using fixed effect models, and qualitative data were pooled using narrative synthesis. Primary outcomes were asthma or asthma-like symptoms. The results were grouped according to population (general, asthmatic, and ibuprofen-hypersensitive), comparator type (active and non-active) and follow-up duration (short- and long-term).
RESULTS: Comparing ibuprofen with active comparators, there was no evidence of a higher risk associated with ibuprofen over both the short and long term in either the general or asthmatic population. Comparing ibuprofen use with no active alternative over a short-term follow-up, ibuprofen may provide protection against asthma-like symptoms in the general population when used to ease symptoms of fever or bronchiolitis. In contrast, it may cause asthma exacerbation for those with pre-existing asthma. However, in both populations, there were no clear long-term follow-up effects.
CONCLUSIONS: Ibuprofen use in children had no elevated risk relative to active comparators. However, use in children with asthma may lead to asthma exacerbation. The results are driven by a very small number of influential studies, and research in several key clinical contexts is limited to single studies. Both clinical trials and observational studies are needed to understand the potential role of ibuprofen in childhood asthma pathogenesis.
A measurement system and calculation method for the concentration distribution of oxyhemoglobin and deoxyhemoglobin in human tissues are provided. The measurement system includes an array of hemoglobin sensor modules, a control system, a signal analysis device and a display system. The hemoglobin sensor module includes a light source transmitter and a photoelectric sensor, which are used to emit and receive light respectively. When the control system triggers the hemoglobin sensor module to emit light, it controls multiple photoelectric sensors to receive the emitted light and upload relevant data. The signal analysis system evaluates the tissue blood oxygen concentration inside human tissues based on the emitted light, and proposes a tomographic three-dimensional reconstruction method. Based on the hemoglobin measurement system and detection method, this patent provides a low-cost, easy-to-use evaluation method for evaluating the blood circulation health level of human tissues.
An implanted medical device (e.g. infusion pump) and handheld communication device communicate with one another via telemetry wherein transmitted messages have enhanced numbers of and/or regularity of bit transitions to minimize the risk of synchronization loss between transmitted bits of data and received bits of data. Bit transitions for portions of messages may be enhanced by applying a pseudo-randomization scheme to those portions of messages that are transmitted in a way that allows the receiver to extract the original data from the received randomized data. Preferred randomization techniques modify (i.e. randomize) the data using a CRC value that is being accumulated while simultaneously causing the modified data to modify subsequent accumulation of the CRC itself. Upon reception, the reversal of data randomization occurs so that the intended message is appropriately received.
The invention relates to a process for preparing capsules used for the beauty treatment, which is a natural extractive without any toxic and side effect. The preparation technology is simple, the immune can be improved, and the effects of beauty treatment and spot removing are obvious. The invention is prepared by camel placenta powder 5-10 weight parts, safflower powder 5-10 weight parts, the extractive powder of the grape seed 5-15 weight parts, and salad oil 8-30 weight parts. The camel placenta powders are acquired to be cleaned clearly and cut up, after weighing, the camel placenta powders are put into the tray and have the dehydration in low temperature, wherein the temperature is controlled at 40-70 DEG C. After the dehydration of 8-12 hours, the smashing and the cribble, a powder 1 is achieved after the microwave germ-killing for 3 to 5 minutes. After the smashing and the cribble of the extractive powders of the grape seeds, a powder 2 is achieved. Safflowers are carefully chosen and dried, and the smashing and the criddle are 80-120 mesh sizes, further after the sterilization, a powder 3 is achieved. The powder 1, the powder 2 and the powder 3 are mixed together with the salad oil and after the low-temperature ultramicro comminuting, an even turbid liquor is achieved. Under the sterilization of 100 DEG C, the medicament is filled into capsules and packed into bottles, then after the certification, the CO60 sterilization and the packaging, the finished product is achieved.
Preoperative 5FU based chemoradiotherapy is still the standard of treatment for locally advanced rectal cancer. About 15-20% of patients would achieve pathologic complete response (pCR) after neoadjuvant CRT, and the survival outcome was much better than that of non-pCR. However, distant metastasis would occur in about 30% of patients even after CRT. To improve the survival of rectal cancer patients, we hope to improve the pCR rate. In our previous FOWARC study, mFOLFOX6 with radiation had the pCR rate of 27.5%. It had been reported that adding FOLFOX after neoadjuvant chemo radiation in locally advanced rectal cancer would improve pCR rate. Nowadays, induction or consolidation chemotherapy or concurrent chemoradiotherapy had been used in clincal practice. Here, we are going to evaluate the safety and efficacy of total neoadjuvant therapy in real world.
In the United States, patients dependent upon parenteral nutrition (PN) receive parenteral fat emulsions composed of soybean oils. Lipids are necessary in PN dependent patients due to their high caloric value and essential fatty acid content. They have been implicated in predisposing patients to PN associated liver disease. Phytosterols such as those contained in soybean oils are thought to have a deleterious effect on biliary secretion.

Children requiring prolonged PN are at risk for developing PN associated liver disease. We hypothesize that although omega-6 fatty acid emulsions prevent fatty acid deficiency, they are not cleared in a manner similar to enteral chylomicrons and therefore accumulate in the liver and resulting in steatotic liver injury. We further hypothesize that a fat emulsion comprised of omega-3 fatty acids (i.e., fish oil) such as Omegaven™ would be beneficial in the management of steatotic liver injury by its inhibition of de novo lipogenesis, the reduction of arachidonic acid-derived inflammatory mediators, prevention of essential fatty acid deficiency through the presence of small amounts of arachidonic acid, and improved clearance of lipids from the serum. Animal studies have shown that IV fat emulsions (IFE) such as fish oil that are high in eicosapentaenic and docashexaaenoic acid reduce impairment of bile flow which is seen in cholestasis caused by conventional fat emulsions. Intravenous omega three fatty acids may be well tolerated and might reduce the inflammatory effect in the liver of prolonged PN exposure and could potentially reverse any hepatic dysfunction due to PN/IFE use. By administering Omegaven™ in place of conventional phytosterol/soybean fat emulsions we may reverse or prevent the progression of PN associated cholestasis and thus allow the patient to be maintained on adequate PN until they are able to ingest adequate nutrition enterally.
602274 Propynylaminoindan (e.g., Rasagiline) transdermal compositions are provided. Aspects of the transdermal compositions include a matrix of the propynylaminoindan in a pressure sensitive adhesive comprising a carboxylated polymer comprising –COOH functional groups. In some instances, the matrix further includes a weak base that may be a cationic acrylic copolymer. Also provided are methods of using the transdermal compositions and kits containing the transdermal compositions. The transdermal composition may be used to treat Parkinson’s disease, Alzheimer’s disease, a memory disorder or stroke. The carboxylated polymer may be a acrylate-vinyl acetate copolymer.
Animal supplements comprise Melissa Officinalis (lemon balm) and L-Theanine in combination. The Melissa Officinalis may be present as an extract of Melissa Officinalis, or as one or more parts (such as leaves) of Melissa Officinalis. The active constituents may be mixed with excipients or carriers, and the supplement may comprise a powder, suspension, solution, paste, pellet, powder, granules, tablet, capsule, gel, syrup, parenteral dose, beverage, or foodstuff. The supplement may be used to modify animal behaviour, preferably by calming the animal. The supplement may be used to treat itchiness. The animal may be a cat, dog, cow or horse. The supplement is preferably used for horses, and may be used to improve gait and performance of horses in dressage. The Melissa Officinalis and L-Theanine are preferably in a ratio of 1:1.
Long-term carcinogenicity studies with irinotecan were not conducted. Rats were, however, administered intravenous doses of 2 mg/kg or 25 mg/kg irinotecan once per week for 13 weeks (in separate studies, the 25 mg/kg dose produced an irinotecan C maxand AUC that were about 7.0 times and 1.3 times the respective values in patients administered 125 mg/m 2weekly) and were then allowed to recover for 91 weeks. Under these conditions, there was a significant linear trend with dose for the incidence of combined uterine horn endometrial stromal polyps and endometrial stromal sarcomas. Irinotecan was clastogenic both in vitro (chromosome aberrations in Chinese hamster ovary cells) and in vivo(micronucleus test in mice). Neither irinotecan nor its active metabolite SN-38 was mutagenic in the in vitroAmes assay. 

No significant adverse effects on fertility and general reproductive performance were observed after intravenous administration of irinotecan in doses of up to 6 mg/kg/day to rats and rabbits; however, atrophy of male reproductive organs was observed after multiple daily irinotecan doses both in rodents at 20 mg/kg and in dogs at 0.4 mg/kg. In separate studies in rodents, this dose produced an irinotecan C maxand AUC about 5 and 1 times, respectively, of the corresponding values in patients administered 125 mg/m 2weekly. In dogs this dose produced an irinotecan C maxand AUC about one-half and 1/15 th, respectively, of the corresponding values in patients administered 125 mg/m 2weekly.
PURPOSE: Children who require specialist outpatient care typically wait substantial periods during which their condition may progress, making treatment more difficult and costly. Timely and effective therapy during this period may reduce the need for lengthy specialist care. This study evaluated the cost-effectiveness of an individualized, evidence-informed, web-based program for children with urinary incontinence awaiting a specialist appointment (Electronic Advice and Diagnosis Via the Internet following Computerized Evaluation [eADVICE]) compared to usual care. eADVICE was supervised by a primary physician and delivered by an embodied conversational agent.
MATERIALS AND METHODS: A trial-based cost-effectiveness analysis was performed from the perspective of the health care funder as a substudy of eADVICE, a multicenter, waitlist-controlled, randomized trial. Outcomes measures were incremental cost per incremental change in continence status and quality of life on an intention-to-treat basis. Uncertainty was examined using cost-effectiveness planes, scenarios, and 1-way sensitivity analyses. Costs were valued in 2021 Australian dollars.
RESULTS: The use of eADVICE was found to be cost saving and beneficial (dominant) over usual care, with a higher proportion of children dry over 14 days at 6 months (risk difference 0.13; 95%CI 0.02-0.23, P = .03) and mean health care costs reduced by $188 (95%CI $61-$315) per participant.
CONCLUSIONS: An individualized, evidence-informed, web-based program delivered by an embodied conversational agent is likely cost saving for children with urinary incontinence awaiting a specialist appointment. The potential economic impact of such a program is favorable and substantial, and may be transferable to outpatient clinic settings for other chronic health conditions.
FIELD: medicine; medical engineering. SUBSTANCE: method involves preliminarily drying bee-bread in convection mode. Cooling, separating bee-bread grains, making ozone disinfection, mixing and grinding product with vitamins, microelements and amino acids and final drying in vacuum chamber is carried out. The bee-bread grains are taken from honeycombs and additionally dried in industrial pseudo-liquefied air layer to reach humidity contents of 8%. Ozone disinfection is carried out at the last stage of drying process in the pseudo-liquefied air layer. The product is delivered for being mixed with additional ingredients and ground, using pneumatic transport means. Powder mixture is delivered into vacuum chamber where repeated disinfection is carried out using formaldehyde vapor and the powder is finally dried to reach humidity contents being not greater than 1%. Then, the powder mixture is ground once more to produce homogeneous mass. The device has tightly closed heat-insulated chamber for performing convection drying, cooling chamber 2, separator-grinder, chamber for drying in pseudo-liquefied air layer, aerobic ozone disinfection chamber, air ducts, ventilators, electric heaters, ozone generator, buffer capacity, pneumatic transport pipeline, ventilator pipeline, dust extractor- precipitator, sleeve filter, accumulating reservoir, mixer, grinder, vacuum chamber having device for repeatedly disinfecting the product, infrared heat radiator, pipeline for cooling external surface, water ring pump and damp-ejecting vacuum pump. EFFECT: low cost production process; high quality of product; high product output. 7 cl, 1 dwg
Bone marrow stromal cells (BMSCs) can be grown from bone marrow aspirates and biopsies, and are being used to treat a number of disorders including: graft-versus-host disease (GVHD), ischemic heart disease, peripheral vascular disease and autoimmune diseases. The purpose of this protocol is to collect bone marrow aspirates and biopsies from healthy volunteers to produce clinical grade BMSCs to treat Clinical Center patients and to develop new methods for producing and assessing the quality of BMSCs. In some cases, the donors will be the recipients of the ex vivo expanded cells (autologous transplantation). In other cases, no matching of HLA or other antigens is required between the marrow donor and the BMSC recipient, so the donors will be required to meet the same healthy history and infectious disease marker screening criteria as volunteer blood donors. The BMSCs will be produced in the GMP Clinical Cell Processing Laboratory, located in the Cell Processing Section (CPS), Department of Transfusion Medicine (DTM), Clinical Center. After the BMSCs are produced by the Cell Processing Laboratory, they will be infused directly into Clinical Center patients on protocol, or cryopreserved and stored, and used as they are needed to treat Clinical Center patients. Up to 250 subjects will be enrolled in this study. This protocol will provide a mechanism for banking fresh and frozen BMSC products that can be used for patient care and research. This is not a treatment protocol. Subjects receiving these BMSC products will be enrolled in specific BMSC treatment protocols.
AIM: Cerium oxide, particularly in nanoparticle form (nanoceria), has been investigated for biomedical applications as a promising new agent for treating several pathologies. The aim of the present study was to characterize the pharmacologic effects of nanoceria in an animal model of chronic kidney disease.
METHODS: We created the chronic kidney disease animal model by feeding rats a 0.25% adenine diet. Male Wistar rats were divided into five groups: normal diet, 0.25% adenine diet, or adenine diet containing three different doses or durations of nanoceria treatment. Blood was collected weekly from the tail veins of each rat and analyzed for renal function markers. After 5 weeks, various biochemical markers in serum, plasma, and urine were also analyzed.
RESULTS: In the adenine-treated group, body weight was significantly decreased, and the kidneys lost much of their healthy reddish color and became lumpy and white in appearance. In addition, levels of serum creatinine, blood urea nitrogen, and plasma uremic toxins were significantly increased in adenine-treated rats compared with controls. Renal functional and structural damage in adenine diet model rats tended to be ameliorated by nanoceria ingestion. The high-dose cerium-treated group maintained reddish areas in the kidneys, and the increases in biomarker levels of creatinine, blood urea nitrogen, and inorganic phosphorus were markedly reduced, regardless of treatment duration.
CONCLUSIONS: Ingestion of nanoceria may be effective for improving or preventing renal damage caused by adenine. Geriatr Gerontol Int 2024; 24: 88-95.
AIC100 CAR T Cell Dose Level 4 (Flat Dose): 7.5 x 10e8 CAR T cells. The proposed escalation dose of Cohort 4 may be evaluated, if needed, based on ongoing safety and efficacy data.
Impaired long-term memory, a complication of traumatic stress including hemorrhage shock and resuscitation (HSR), has been reported to be associated with multiple neurodegenerations. The ventral tegmental area (VTA) participates in both learned appetitive and aversive behaviors. In addition to being prospective targets for the therapy of addiction, depression, and other stress-related diseases, VTA glutamatergic neurons are becoming more widely acknowledged as powerful regulators of reward and aversion. This study revealed that HSR exposure induces memory impairments and decreases the activation in glutamatergic neurons, and decreased β power in the VTA. We also found that optogenetic activation of glutamatergic neurons in the VTA mitigated HSR-induced memory impairments, and restored β power. Moreover, hydrogen sulfide (H2S), a gasotransmitter with pleiotropic roles, has neuroprotective functions at physiological concentrations. In vivo, H2S administration improved HSR-induced memory deficits, elevated c-fos-positive vesicular glutamate transporters (Vglut2) neurons, increased β power, and restored the balance of γ-aminobutyric acid (GABA) and glutamate in the VTA. This work suggests that glutamatergic neuron stimulation via optogenetic assay and exogenous H2S may be useful therapeutic approaches for improving memory deficits following HSR.
The present invention relates to microparticles containing moxidectin and a method for preparing the same. In the conventional case, a heartworm preventative has the short half-life and has to be administered daily or monthly. Unlike the conventional heartworm preventative, when microparticles including moxidectin are administered, the moxidectin is continuously released for three months or longer, and thus, the heartworm preventing effect is maintained. In addition, microparticles with a constant average diameter and a narrow distribution width of the diameter can be prepared. Accordingly, even when the microparticles are administered, the initial over-release of moxidectin is prevented. By controlling the release of the drug, the concentration of microparticles valid for more than three months can be constantly maintained. When the same is administered with an injector, it is possible to reduce feeling of irritation caused by foreign matter and pain.
The present invention relates to a medicine, particularly to a bone-setting medicine for treating fractures and soft tissue injury. The bone-setting medicine is prepared from 60 wt% of tender epidermis powder of sorghum stalk and 40 wt% of cock bone powder. The tender epidermis powder of sorghum stalk and the cock bone powder are ground by using the conventional method for common traditional Chinese medicine powder, evenly mixed, made into traditional Chinese medicine powder and made into capsules. The bone-setting medicine for treating fractures and soft tissue injury is preferably taken orally, and has favorable effect when taken with an amount of yellow wine. The present invention has the advantages that the bone-setting medicine has specially good effect on fast anastomosis cure after bones are reset, and can eliminate tumescence, alleviate pain, relieve inflammation, supply porosis with active substances and quicken the union of fractures. The bone-setting medicine has the advantages of favorable curative effect and quick effect taking. When the medicine is used, patients can not feel painful, and the medicine does not have toxic or side effect.
Group Drug Counseling (GDC) is a standard 12-week, 90-minute mixed-gender group therapy. The overall goals of GDC are to 1) help patients to achieve abstinence from all substances of abuse; 2) educate patients regarding recovery from substance use disorders; 3) increase patients' self-awareness of the problems that their substance use disorder has caused; 4) encourage patients to give mutual support; and 5) help patients learn new ways to cope with problems in order to prevent relapse. The GDC was chosen as the comparison group to approximate group drug counseling that is consistent with treatment as usual within the community.
The present invention provides a new blood vessel generating inhibitor, LK68, the consistence of an amino acid sequence with structural domains IV 36, IV 37 and IV 38 of human apolipoprotein (a) kringle, a cDNA sequence of encoding the LK68, a recombination expression carrier with cDNA, a recombination microbe converted by the recombination expression carrier, a new purpose of the LK68 as an anticancer agent, and a method for treating diseases induced by blood vessel generation. The LK68, LK6, LK7 and LK8 denote suppressing activity for cultured esoderma cell proliferation and esoderma cell migration; the LK68 and a single kringle also suppress the normal development of capillary vessels in chick chorioallantoic membranes (CAM). The system administration of the LK68 suppresses the growth of primary tumors and is relevant to the suppression of blood vessel generation which induces the tumors. Therefore, LK68 protein and the single kringle or functional equivalents of the LK68 protein and the single kringle can be used for developing an effective anticancer agent. The anticancer agent has high efficiency for diseases comprising cancer, rheumatoid arthritis, psoriasis, eye blood vessel generating diseases, etc. induced by the blood vessel generation.